Market capitalization | $352.55m |
Enterprise Value | $375.55m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 16.91 |
P/S ratio (TTM) P/S ratio | 15.87 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 11.41% |
Revenue (TTM) Revenue | $22.21m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
5 Analysts have issued a Senseonics forecast:
5 Analysts have issued a Senseonics forecast:
Sep '24 |
+/-
%
|
||
Revenue | 22 22 |
11%
11%
|
|
Gross Profit | -2.33 -2.33 |
189%
189%
|
|
EBITDA | -76 -76 |
0%
0%
|
EBIT (Operating Income) EBIT | -78 -78 |
0%
0%
|
Net Profit | -80 -80 |
154%
154%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Senseonics Holdings, Inc. engages in the design, development, and commercialization of an implantable continuous glucose monitoring system for people with diabetes. Its primary product is the brand Eversense, a glucose monitoring device which includes sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.
Head office | United States |
CEO | Timothy Goodnow |
Employees | 132 |
Founded | 2014 |
Website | www.senseonics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.